Volume 73, Issue 6, Pages 292-299 (June 2010)

3 of 13

ABSTRACT

ABSTRACT + REFS

FULL-TEXT PDF (198 KB)

Cetuximab-based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Experience From an Area in Which Betel Nut Chewing Is Popular

Received 30 December 2009; accepted 31 May 2010.

Background

This study was undertaken to evaluate the efficacy and safety of cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in an area in which betel nut chewing is popular.

Methods

Twenty-five patients were enrolled in the study from 2004 to 2008, of whom 13 received first-line cetuximab plus chemotherapy and 12 received second-line cetuximab with or without chemotherapy after the failure of cisplatin.

Results

In the first-line chemotherapy group, the overall response [complete response (CR) plus partial response (PR)] was 54% and disease control rate [CR + PR + stable disease (SD)] was 62%. In the cisplatin-failure therapy group, the overall response was 16.7% and disease control rate was 50%. Median overall survival (OS) and time to progression (TTP) in the first-line chemotherapy group were 857 days and 147 days, respectively. In the cisplatin-failure therapy group, median OS and TTP were 371 days and 136 days, respectively. The most common grade 3/4 toxicity in both groups of patients was infection/fever (23% in the first-line group, 50% in the cisplatin-failure group), followed by neutropenia (23% in the first-line group, 25% in the cisplatin-failure group).

Conclusion

Cetuximab-based therapy is an effective and safe treatment choice for recurrent/metastatic HNSCC in areas where betel nut chewing is popular.

Key Words: betel nut , cetuximab , head and neck cancer , taxane

No full text is available. To read the body of this article, please view the PDF online.

Article Outline

• Abstract

• References

• Copyright

References

1. 1 Department of Health, Executive Yuan, R.O.C. . Cancer Registry Annual Report in Taiwan Area . Taipei, R.O.C.: Department of Health, Executive Yuan; 2006; .

2. 2 Ko YC , Huang YL , Lee CH , Chen MJ , Lin LM , Tsai CC . Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan . J Oral Pathol Med . 1995;24:450–453 . MEDLINE | CrossRef

3. 3 Hsieh LL, Wang PF, Chen IH, Liao CT, Wang HM, Chen MC, et al Characteristics of mutations in the p53 genes in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in Taiwanese . Carcinogenesis . 2001;22:1497–1503 . MEDLINE | CrossRef

4. 4 Ho PS , Yang YH , Shieh TY , Chen CH , Tsai CC , Ko YC . Ethnic differences in the occurrence of oropharyngeal cancer in Taiwan . Public Health . 2007;121:765–773 .

5. 5 Lee JM . The synergistic effect of cigarette taxes on the consumption of cigarettes, alcohol and betel nuts . BMC Public Health . 2007;7:121 . CrossRef

6. 6 Thomas SJ , Bain CJ , Battistutta D , Ness AR , Paissat D , Maclennan R . Betel quid not containing tobacco and oral cancer: a report on a case-control study in Papua New Guinea and a meta-analysis of current evidence . Int J Cancer . 2007;15:1318–1323 .

7. 7 Nair U , Bartsch H , Nair J . Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms . Mutagenesis . 2004;19:251–262 . MEDLINE | CrossRef

8. 8 Goan YG , Chang HC , Hsu HK , Chou YP , Cheng JT . Risk of p53 gene mutation in esophageal squamous cell carcinoma and habit of betel quid chewing in Taiwanese . Cancer Sci . 2005;96:758–765 . MEDLINE | CrossRef

9. 9 Chiang WF, Liu SY, Yen CY, Lin CN, Chen YC, Lin SC, et al. Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas . Oral Oncol . 2008;44:270–276 . Abstract | Full Text | Full-Text PDF (878 KB) | CrossRef

10. 10 Chen IH , Chang JT , Liao CT , Wang HM , Hsieh LL , Cheng AJ . Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis . Br J Cancer . 2003;18:681–686 .

11. 11 Simon MA . Receptor tyrosine kinases: specific outcomes from general signals . Cell . 2000;103:13–15 . MEDLINE | CrossRef

12. 12 Olayioye MA , Neve RM , Lane HA , Hynes NE . The ErbB signaling network: receptor heterodimerization in development and cancer . EMBO J . 2000;19:3159–3167 . MEDLINE | CrossRef

13. 13 Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck . N Engl J Med . 2006;354:567–578 . CrossRef

14. 14 Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck . J Clin Oncol . 2005;23:5568–5577 . CrossRef

15. 15 Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, et al Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck . J Clin Oncol . 2005;23:5578–5587 . CrossRef

16. 16 Burtness B , Goldwasser MA , Flood W , Mattar B , Forastiere AA . Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study . J Clin Oncol . 2005;23:8646–8654 . CrossRef

17. 17 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al New guidelines to evaluate the response to treatment in solid tumors . J Natl Cancer Inst . 2000;92:205–216 . MEDLINE

18. 18 National Cancer Institute . Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0 . Available at http://ctep.info.nih.gov 1999; [Data accessed: April 20, 2009] .

19. 19 Clavel M, Vermorken JB, Cognetti F, Cappelaere P, Mulder PHM, Schornagel JH, et al Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck . Ann Oncol . 1994;5:521–526 . MEDLINE

20. 20 Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group . J Clin Oncol . 2005;23:3562–3567 . CrossRef

21. 21 Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study . J Clin Oncol . 1992;10:1245–1251 .

22. 22 Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of head and neck . J Clin Oncol . 1992;10:257–263 .

23. 23 Chang PM, Teng HW, Chen PM, Chang SY, Chu PY, Tsai TL, et al Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer . J Chin Med Assoc . 2008;71:336–341 . Abstract | Full-Text PDF (184 KB) | CrossRef

24. 24 Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C, et al EGFR FISH assay predicts for response to cetuximab in chemotherapy-refractory colorectal cancer patients . Ann Oncol . 2008;19:717–723 . CrossRef

25. 25 Baur M, Kienzer HR, Schweiger J, DeSantis M, Gerber E, Pont J, et al Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial . Cancer . 2002;94:2953–2958 .

26. 26 Clark JI, Hofmeister C, Choudhury A, Matz G, Collins S, Bastian R, et al Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma . Cancer . 2001;92:2334–2340 .

27. 27 Gedlicka C, Formanek M, Selzer E, Burian M, Kornfehl J, Fiebiger W, et al Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck . Oncology . 2002;63:145–150 .

28. 28 Tishler RB, Posner MR, Wirth LJ, Balboni T, Costello R, Goguen L, et al Cetuximab added to docetaxel, cisplatin, 5-fluorouracil induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: a phase I study . J Clin Oncol . 2008;26:6001 . CrossRef

29. 29 Argiris AE, Gibson MK, Heron DE, Smith RP, Ferris RL, Lai SY, et al Phase II trial of neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (X), P, and E in locally advanced head and neck cancer (HNC) . J Clin Oncol . 2008;26:6002 .

30. 30 Gebbia V , Giuliani F , Valori VM , Agueli R , Colucci G , Maiello E . Cetuximab in squamous cell head and neck carcinomas . Ann Oncol . 2007;18(Suppl):vi5–vi7 . CrossRef

31. 31 Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al Open-label, uncontrolled, multicenter phase III study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy . J Clin Oncol . 2007;25:2171–2177 . CrossRef

32. 32 Vermorken JB , Herbst RS , Leon X , Amellal N , Baselga J . Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies . Cancer . 2008;112:2710–2719 .

33. 33 Haddad RI , Shin DM . Recent advances in head and neck cancer . N Engl J Med . 2008;359:1143–1154 . CrossRef

a Division of Hematology-Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.

b Department of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.

c Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.

d Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.

Correspondence to: Dr Muh-Hwa Yang, Institute of Clinical Medicine, National Yang-Ming University, 155, Section 2, Li-Nong Street, Peitou, Taipei 112, Taiwan, R.O.C.

PII: S1726-4901(10)70064-2

doi:10.1016/S1726-4901(10)70064-2

3 of 13